On April 11, Nature Medicine published a paper about what happened in the brains of people with depression who were treated with either an antidepressant called escitalopram or psilocybin, the active ingredient in magic mushrooms.

Clinics in 10 U.S. cities — including one in Western North Carolina — have been approved by the FDA to expand patient access to MDMA. The recreational drug also known as Ecstasy, will be a treatment for post-traumatic stress disorder.

2022-05-10 This Psychedelic Drugs Market report makes available statistics on the current state of the industry as a valuable source of guidance and direction for companies and investors interested in…

2022-05-04 The historic tale of conquistador Hernán Cortes’s encounter with Aztec emperor Moctezuma is one often shared to recount the origins of European colonization of the Americas. Moctezuma showed great…

A new healing retreat known as “Dimensions Algonquin Highlands” is gearing up to open in Ontario’s hinterland, a three-hour car trip from Toronto. But that’s not the only ‘trip’ involved with this destination.

2022-04-22 In an interview with Pharmacy Times, Jim Gilligan, PhD, interim CEO, president, and chief scientific officer of Tryp Therapeutics, discussed a new trial investigating the potential use of psilocybin-assisted…